Top in GI: Duodenal mucosal resurfacing, subcutaneous Entyvio
Click Here to Manage Email Alerts
Coverage of the United European Gastroenterology virtual conference made up the top stories in gastroenterology last week.
One presentation showed that more than half of patients with diabetes who underwent duodenal mucosal resurfacing remained insulin free at 1 year. Another presentation demonstrated the safety and efficacy of subcutaneous Entyvio (vedolizumab, Takeda) for long-term ulcerative colitis maintenance.
Read these and more top stories in gastroenterology below:
More than half of patients with diabetes off insulin after duodenal resurfacing
More than half of patients who underwent duodenal mucosal resurfacing remained insulin free and saw improved metabolic parameters at 6 months and 1 year, study results showed. Read more.
Subcutaneous Entyvio safe, effective for long-term maintenance of UC
The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis. Read more.
Childhood allergies linked with increased adolescent IBS risk
Researchers reported that allergy-related diseases, including asthma and food hypersensitivity, in childhood were associated with an increased risk of having irritable bowel syndrome at age 16 years. Read more.
Immediate vs. postponed drainage yields similar results for necrotizing pancreatitis
Immediate catheter drainage was not superior to postponed drainage in patients with infected necrotizing pancreatitis, according to study results. Read more.
Mirikizumab demonstrates efficacy up to 52 weeks in Crohn’s disease
Phase 2 data support the safety and efficacy of mirikizumab (Eli Lilly) in patients with Crohn’s disease, researchers said. Read more.